US government signs $354 million generics and API manufacturing contract with Phlow
![](/46/pdcnewsitem/11/00/02/HLN00CPO-US-drug-map.jpg)
Pharma start-up will use continuous manufacturing to shore up supply chain of essential medicines
The US government has signed a USD 354 million contract with pharma start-up Phlow Corporation to manufacture generics and active pharmaceutical ingredients (APIs) needed for drugs in short supply, including COVID-19 treatments, in a move to create the nation’s first strategic stockpile of key ingredients and reduce its dependence on overseas supply.
The four-year contract, awarded by the Biomedical Advanced Research and Development Authority, could be extended up to USD 812 million over ten years, making it one of the largest awards in BARDA’s history. Under the terms of the agreement, Phlow will lead a team of private sector entities that includes API and intermediates manufacturer Ampac Fine Chemicals, Civica Rx and the Medicines for All Institute.
Phlow said it has started manufacturing chemical precursor ingredients, APIs and finished dosage forms for over a dozen medicines to treat hospitalized patients with COVID-19-related illnesses.
“Many of these medicines are in shortage and have previously been imported from foreign nations,” the company said in a statement.
Phlow said it had also delivered over 1.6 million doses of five generic drugs used to treat COVID-19 to the US Strategic National Stockpile, including medicines to sedate patients requiring ventilator support, painkillers and antibiotics.
The company said it is also building the US’ first Strategic API Reserve (SAPIR), a long-term stockpile to secure key ingredients.
The decision to award the contract to a new company rather than an established manufacturer has raised eyebrows.
On its website, Virginia-based Phlow markets itself as a solution to a “broken” US pharmaceutical supply chain “dangerously dependent on foreign suppliers.” It says traditional batch manufacturing, which it describes as a multi-step, lengthy process that involves the use of large-scale, labour-intensive equipment, has led to API production being mainly centred in China and India, where labour costs are low.
The company says all its pharmaceutical products will be manufactured in the US by continuous manufacturing, which it describes as a modern process “that maximizes throughput, increases productivity, and lowers labour requirements.”
Phlow’s business model chimes with the Trump administration’s desire to refocus API manufacturing in the US, particularly as the current coronavirus pandemic has placed greater emphasis on security of drug supply.
“For far too long, we've relied on foreign manufacturing and supply chains for our most important medicines and active pharmaceutical ingredients while placing America's health, safety, and national security at grave risk,” said Peter Navarro, director of the White House Office of Trade and Manufacturing Policy, commenting on the deal.
In April, Phlow signed a USD 6 million contract from the US Department of Health and Human Services to secure a supply of medications and APIs at risk of shortage due to the COVID-19 pandemic.
Non-profit pharma firm Civica Rx will manufacture the finished dosage product on the same site as Phlow's precursor and API production and distribute via a network of more than 1,200 hospitals.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance